英文名稱 | Tofacitinib | Tasocitinib | CP-690550 |
---|---|
中文名稱 | 托法替尼 | 托法替布 |
CAS號(hào) | 477600-75-2 |
分子式 | C16H20N6O |
分子量 | 312.37 |
外觀 | White or off-white powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專享價(jià) | 數(shù)量 |
---|---|---|---|---|
20 mg | In-stock | ¥300.00 | 登錄后可見(jiàn) | |
50 mg | In-stock | ¥400.00 | 登錄后可見(jiàn) | |
100 mg | In-stock | ¥650.00 | 登錄后可見(jiàn) |
英文名稱 | Tofacitinib | Tasocitinib | CP-690550 |
---|---|
中文名稱 | 托法替尼 | 托法替布 |
CAS號(hào) | 477600-75-2 |
分子式 | C16H20N6O |
分子量 | 312.37 |
外觀 | White or off-white powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. Tofacitinib inhibits the expression of antiapoptotic BCL-A1 and BCL-XL in human plasmacytoid dendritic cells (PDC) and induced PDC apoptosis.
Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS.
PMID: 28087469 DOI: 10.1016/j.pupt.2017.01.002
PMID: 22899318 DOI: 10.1002/art.34649
Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.
PMID: 24890727 PMCID: PMC4106678 DOI: 10.4049/jimmunol.1400063